Clinical trials: Systemic Lupus Erythematous (SLE)
COVID-19
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
There is a pandemic in the world by COVID-19. Currently, the pharmacological curative or prophylactic treatments for this infection are not known.
- Trial name
- PREPCOV (NCT04481633)
- Testing
- COVID 19 serology, COVID 19 Self-Questionnaire
- Where
- 12 sites in France
- Volunteers
- 547 people
- Sponsor
- University Hospital, Toulouse
Systemic Lupus Erythematous (SLE)
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus
Background: The immune system is the body's defense against bacteria and other harmful invaders. In people with systemic lupus erythematosus (SLE), the immune system becomes overactive and attacks healthy cells by mistake.
- Trial name
- NCT04233164
- Testing
- Solu-Medrol 1mg/kg, Solu-Medrol 250 mg
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum